Viking Therapeutics, Inc.(股票代码:VKTX)10月24日盘中大涨逾20%,主要受到投资者对公司肥胖症新药前景预期向好的推动。
作为一家专注于开发治疗代谢和内分泌疾病新药的生物制药公司,Viking Therapeutics目前正在研发一款口服肥胖症药物VK2735。最新消息显示,公司将在即将举行的肥胖周会议上公布VK2735的关键临床试验结果,这引发了市场对该产品前景的乐观预期。
分析人士预计,随着服药周期的延长,VK2735的减重效果有望进一步提升。另外,Viking Therapeutics在最新临床试验中亦已评估了更高的剂量,这为后续研发提供了更多选择空间。如果最终试验结果良好,VK2735有望成为Viking Therapeutics的一款潜在的增长引擎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.